BioCryst Pharma secures $350m from Royalty Pharma, OMERS
BioCryst Pharmaceuticals, a Durham, North Carolina-based developer of small molecule medicines for rare diseases, has raised $350 million in royalty financing.
22 November 2021•4 mins read
BioCryst Pharmaceuticals, a Durham, North Carolina-based developer of small molecule medicines for rare diseases, has raised $350 million in royalty financing.
Stonepeak completes acquisition of 65% Castrol stake from BP
55 minutes ago · 1 min read
Livingbridge backs launch of accounting group Apteus after seven acquisitions
3 hours ago · 2 mins read
DPE-backed CirQono acquires Saxony demolition firm ORA in add-on deal
6 hours ago · 2 mins read
Charterhouse agrees to sell Vermeg stake to Advent, with ADIA co-investing
6 hours ago · 2 mins read
Apollo funds complete minority investment in Alpine-backed Apex Service Partners
30 October 2026 · 2 mins read
Rainier Partners invests in Texas auto insurance MGA platform Apex
30 October 2026 · 2 mins read
Stonepeak completes carve-out of BMO’s transportation and vendor finance units
30 October 2026 · 2 mins read
